| 彭东徐可为王荣辉何燕黄德娟刘徽婷潘科.TRAb 在Graves病131I治疗中的临床价值[J].现代生物医学进展英文版,2014,14(17):3276-3279. |
| TRAb 在Graves病131I治疗中的临床价值 |
| Clincal Value of SerumTRAb in Graves' Disease Beforeand After 131I Therapy |
| |
| DOI： |
| 中文关键词: 格雷夫斯病 促甲状腺激素受体抗体 131 碘治疗 电化学发光免疫分析 |
| 英文关键词: Graves' disease Thyrotropin receptor antibodies (TRAb) 131I radiotherapy Electrochemiluminescence immunoassay
assay(ECLA) |
| 基金项目: |
|
| Hits: 889 |
| Download times: 1207 |
| 中文摘要: |
| 摘要目的：探讨促甲状腺激素受体抗体（TRAb）在Graves 病131I治疗中的临床价值。方法：回顾性分析我院经131I治疗的186 例
Graves病患者，与70 例健康对照组分别于131I治疗前及治疗后3、6、12 和18 月采用电化学发光免疫分析法(ECLA)动态检测血清
TRAb、FT3、FT4、TSH 浓度变化，进行统计分析，并计算TRAb 的阳性率。结果：70 例健康对照组TRAb 水平1.09± 0.45 IU/L，186
例Graves病131I治疗前血清TRAb水平9.95± 7.18 IU/L，明显高于健康对照组，两组比较有显著的统计学意义(t=-10.306,P＜0.001)。
131I 治疗3 月后TRAb水平14.81± 10.37 IU/L，明显高于治疗前（t= -5.26, P＜0.001）；131I治疗6 月后TRAb水平12.33± 8.73 IU/L
开始下降，治疗12 月后TRAb水平3.14± 0.87 IU/L明显降低；治疗18 月后TRAb 水平1.19± 0.45 IU/L 与健康对照组比较差异
无统计学意义（t= -1.588,P=0.113）。Graves 病131I 治疗前TRAb 阳性率为93.5%，治疗后3、6、12、18 个月TRAb 阳性率分别为
93.5%、79.6%、27.4%和8.6%。结论：Graves 病131I治疗中检测TRAb 水平具有指导治疗、判断疗效、预测复发等重要的临床价值。 |
| 英文摘要: |
| ABSTRACT Objective:To investigate the clincal value of serum TRAb in Graves' disease before and after 131I therapy.
Methods:A total of 186 patients of Graves' disease and 70 normal controls were included in the study. Serum concentration of TRAb were
measured by ECLA before and at 3,6,12 and 18 months after 131I radiotherapy. Results:The TRAb level of 70 normal controls was
(1.09± 0.45) IU/L. Abnormally higher TRAb level(9.95± 7.18 IU/L) was noted in patients before 131I treatment(t= -10.31,P＜0.001). The
TRAb level increased to (14.81± 10.37 IU/L) at 3 months after 131I therapy (t= -5.26, P＜0.001) ,before it dropped to (12.33± 8.73
IU/L) and (3.14± 0.87 IU/L) at 6 and 12 months respectively (t=-2.89 and t=12.85, P＜0.05).At 18 months after 131I radiotherapy,the
level of TRAb (1.19± 0.45 IU/L) was back to normal with no difference to that of nomal controls(t= -1.59, P＞0.05). Before 131I treatment
of Graves' disease TRAb positive rate was 93.5% and at 3,6, 12,18 months after treatment TRAb positive rates were 93.5%, 79.6%,
27.4% and 8.6%.Conclusion: It is of great significance to measure serum concentrations of TRAb after 131I radiotherapy for Graves'
disease, which is of important clinical value for therapy guidance, efficacy assessment and recurrence prediction. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
